cancerTiming specifications


Unique identifier OMICS_09039
Name cancerTiming
Software type Package/Module
Interface Command line interface
Restrictions to use None
Operating system Unix/Linux, Mac OS, Windows
Programming languages R
License GNU General Public License version 2.0
Computer skills Advanced
Version 3.1.8
Stability Stable
stats, gplots, graphics, IRanges, GenomicRanges, utils, S4Vectors, grDevices, R(≥2.11.0), LearnBayes
Maintained Yes


No version available



  • person_outline Elizabeth Purdom

Publication for cancerTiming

cancerTiming citation


Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline

PMCID: 5008168
PMID: 25711488
DOI: 10.1111/bju.13101

[…] DRESymptoms suggest BOO secondary to BPE , , Patient concern in relation to prostate cancer Abnormal prostate on DRESymptoms suggest BOO secondary to BPE , , Patient concern in relation to prostate cancerTiming:PSA testing should be postponed for: 6 weeks after treatment for UTI1 week after DRE48 hours after vigorous exercise or sexual activity6 weeks after prostate biopsy2 weeks after flu‐like […]

cancerTiming institution(s)
Department of Statistics, University of California, Berkeley, Evans Hall Berkeley, CA, USA; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA; Department of Dermatology, University of California, San Francisco, CA, USA
cancerTiming funding source(s)
National Institute of Health TCGA grant (U24 CA143799); the Anna Fuller fund; the Dermatology Foundation; the American Skin Association; and National Science Foundation grants (DMS-0636667, DMS-1026441)

cancerTiming reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review cancerTiming